Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
NeuBase Therapeutics, Inc. (0001173281)
Standardized SEC financial data for NeuBase Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001173281 · Pharmaceutical Preparations.
Return on equity
-145.6%
Free cash flow
-$29.5M
Current ratio
5.92×
EPS (diluted)
$-1.04
Income statement
USD
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
R&D expense
$17.4M
—
$3.4M
$6.9M
$11.5M
$21.4M
SG&A expense
$5.3M
—
$9.1M
$10.1M
$12.2M
$11.9M
Operating income
-$23.8M
—
-$25.5M
-$17.1M
-$26.6M
-$33.3M
EBITDA
-$22.6M
—
Standardized from NeuBase Therapeutics, Inc.'s SEC filings — per-share figures split-adjusted. Full history via the API.